GSK and Hansoh report Phase III Ris-Rez result in osteosarcoma

ARTEMIS-011 primary endpoint reported met

GSK and its licensor Hansoh Pharma said the pivotal Phase III ARTEMIS-011 trial of risvutatug rezetecan, known as Ris-Rez, met its primary endpoint in China, according to Thepharmaletter.

The companies’ update concerns patients with osteosarcoma whose disease had progressed or relapsed after at least two prior lines of systemic therapy. Thepharmaletter described ARTEMIS-011 as a pivotal Phase III trial.

Ris-Rez is an investigational B7-H3-targeting antibody-drug conjugate. GSK is UK-based, and Hansoh Pharma is identified by Thepharmaletter as the licensor of the treatment.

Reported progression or death finding

Thepharmaletter reported that GSK and Hansoh said Ris-Rez reduced the risk of progression or death by 67% in relapsed osteosarcoma in China.

The reported finding is tied to the ARTEMIS-011 population: patients in China with osteosarcoma that had progressed or relapsed following at least two prior lines of systemic therapy. The companies said the trial met its primary endpoint.

Partnership and development context

The announcement centers on the licensing relationship between GSK and Hansoh Pharma and the clinical development of Ris-Rez. Thepharmaletter’s report identifies the therapy as an investigational B7-H3-targeting antibody-drug conjugate.

For pharmaceutical and biotech sales professionals, the update brings together a named Phase III program, an investigational antibody-drug conjugate, and a reported result in a specified osteosarcoma setting in China. The stated outcome should be understood in the context of the patient population described by GSK and Hansoh Pharma.

Thepharmaletter reported the companies’ statements on the ARTEMIS-011 primary endpoint and the reported reduction in risk of progression or death.